Claims for Patent: 9,724,380

Summary for Patent: 9,724,380

Title:	Method and compositions for synchronizing time of insemination in gilts
Abstract:	Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided.
Inventor(s):	Webel; Stephen Kent (Baylis, IL), Swanson; Mark E. (Princeton Junction, NJ), Kraeling; Robert R. (Sheridan, IN), Johnston; Michael E. (Noblesville, IN)
Assignee:	JBS UNITED ANIMAL HEALTH II LLC (Sheridian, IN)
Application Number:	14/648,182
Patent Claims:	1. A method for synchronizing time of ovulation in a gilt, the method comprising the steps of: administering to the gilt a hormone for synchronizing estrus; administering to the gilt a single dose of a gonadotropin-releasing hormone for synchronizing ovulation, without administration of any other hormone for synchronizing ovulation, wherein the gonadotropin-releasing hormone is administered on the fifth day after the last daily administration of the hormone for synchronizing estrus; and inseminating the gilt, without monitoring estrus, only one time on the sixth day after the last daily administration of the hormone for synchronizing estrus wherein the last daily administration to the gilt of the hormone for synchronizing estrus is day 0. 2. The method of claim 1 wherein the gonadotropin releasing hormone has the formula ##STR00014## or a solvate, a hydrate, or a pharmaceutically acceptable salt thereof wherein R.sup.1 and R.sup.2 are independently in each instance hydrogen, or are independently selected from the group consisting of alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, haloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted, or R.sup.1 and R.sup.2 and the attached carbon form a carbocycle or heterocycle; R.sup.5 is hydrogen or alkyl; and X is hydrogen, or X is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, optionally substituted alkylene-carboxamide, and HNC(O)NR.sup.3R.sup.4, where R.sup.3 and R.sup.4 are in each instance independently selected from the group consisting of hydrogen, alkyl, heteroalkyl and haloalkyl. 3. The method of claim 2 wherein the gonadotropin-releasing hormone is selected from the group consisting of compounds of the formula of claim 2 wherein a) R.sup.1 is 1H-indol-3-yl-methyl, R.sup.2 is hydrogen, X is CH.sub.2(CO)NH.sub.2; R.sup.5 is hydrogen; and the configuration of the carbon to which R.sup.1 is attached is R; b) R.sup.1 is hydrogen, R.sup.2 is hydrogen, X is CH.sub.2(CO)NH.sub.2; and R.sup.5 is hydrogen; c) R.sup.1 is 1H-1-benzyl-imidazol-4-yl-methyl, R.sup.2 is hydrogen, X is ethyl; and R.sup.5 is hydrogen; d) R.sup.1 is 2-methylpropyl, R.sup.2 is hydrogen, X is ethyl; and R.sup.5 is hydrogen; e) R.sup.1 is 2-naphthlymethyl, R.sup.2 is hydrogen, X is CH.sub.2(CO)NH.sub.2; and R.sup.5 is hydrogen; f) R.sup.1 is t-butoxymethyl, R.sup.2 is hydrogen, X is ethyl; R.sup.5 is hydrogen; and the configuration of the carbon to which R.sup.1 is attached is R; g) R.sup.1 is benzyl, R.sup.2 is hydrogen, X is CH.sub.2(CO)NH.sub.2; R.sup.5 is hydrogen; and the configuration of the carbon to which R.sup.1 is attached is R; h) R.sup.1 is t-butoxymethyl, R.sup.2 is hydrogen, X is HN(CO)NH.sub.2; and R.sup.5 is hydrogen; i) R.sup.1 is 1H-indol-3-yl-methyl, R.sup.2 is hydrogen, X is ethyl; and R.sup.5 is hydrogen; j) R.sup.1 is methyl, R.sup.2 is hydrogen, X is hydrogen; R.sup.5 is hydrogen; and the configuration of the carbon to which R.sup.1 is attached is R; k) R.sup.1 is 1H-indol-3-yl-methyl, R.sup.2 is hydrogen, X is ethyl; R.sup.5 is methyl; and the configuration of the carbon to which R.sup.1 is attached is R; l) R.sup.1 is methyl, R.sup.2 is hydrogen, X is CH.sub.2(CO)NH.sub.2; R.sup.5 is hydrogen; and the configuration of the carbon to which R.sup.1 is attached is R; m) R.sup.1 is 4-aminobutyl, R.sup.2 is hydrogen, X is HN(CO)NH.sub.2; R.sup.5 is hydrogen; and the configuration of the carbon to which R.sup.1 is attached is R; n) R.sup.1 is methyl, R.sup.2 is methyl, X is HN(CO)NH.sub.2; and R.sup.5 is hydrogen; and o) R.sup.1 is ethyl, R.sup.2 is hydrogen, X is hydrogen; R.sup.5 is hydrogen; and the configuration of the carbon to which R.sup.1 is attached is R. 4. The method of claim 1 wherein the insemination is an artificial insemination. 5. The method of claim 1 wherein the gonadotropin-releasing hormone is administered in an effective amount and the effective amount of the gonadotropin-releasing hormone is about 200 .mu.g. 6. The method of claim 1 wherein the dose of the gonadotropin-releasing hormone is administered using a method selected from the group consisting of use of a deposition catheter, manual administration, and injection. 7. The method of claim 6 wherein the gonadotropin-releasing hormone is administered using a deposition catheter. 8. The method of claim 6 wherein the gonadotropin-releasing hormone is administered by injection. 9. The method of claim 2 wherein in the formula X is H.sub.2CC(O)NH.sub.2, R.sub.1 is hydrogen, and R.sub.2 is ##STR00015## 10. The method of claim 1 wherein the gonadotropin-releasing hormone is triptorelin. 11. The method of claim 10 wherein the hormone that synchronizes estrus is altrenogest. 12. The method of claim 1 wherein the gonadotropin-releasing hormone is in a composition and the composition comprises methylparaben in an amount of about 0.09% weight per volume, propylparaben in an amount of about 0.01% weight per volume, sodium chloride in an amount of about 0.91% weight per volume, sodium citrate in an amount of about 0.186% weight per volume, L-methionine in an amount of about 0.1% weight per volume, citric acid in an amount of about 0.07% weight per volume, triptorelin in an amount of about 0.01% weight per volume, and methycellulose in an amount that provides a viscosity of about 250 cP to about 400 cP. 13. The method of claim 1 wherein the gonadotropin-releasing hormone is in an excipient selected from the group consisting of buffered saline, a liquid alcohol, a glycol, a glucose solution, an ester, an amide, and sterile water. 14. The method of claim 13 wherein the excipient further comprises a pH buffering agent selected from the group consisting of an acetate buffer, a borate buffer, a carbonate buffer, a citrate buffer, a phosphate buffer, hydrochloric acid, sodium hydroxide, magnesium oxide, monopotassium phosphate, bicarbonate, ammonia, carbonic acid, sodium citrate, citric acid, acetic acid, and disodium hydrogen phosphate. 15. The method of claim 1 wherein the gonadotropin-releasing hormone is administered about 125 to about 133 hours after the last daily administration of the hormone for synchronizing estrus. 16. The method of claim 1 wherein the gonadotropin-releasing hormone is administered about 126 to about 130 hours after the last daily administration of the hormone for synchronizing estrus. 17. The method of claim 1 wherein the gonadotropin-releasing hormone is administered about 126 hours after the last daily administration of the hormone for synchronizing estrus. 18. The method of claim 1 wherein the gonadotropin-releasing hormone is administered about 128 hours after the last daily administration of the hormone for synchronizing estrus. 19. The method of claim 1 wherein the gonadotropin-releasing hormone is administered about 130 hours after the last daily administration of the hormone for synchronizing estrus. 20. The method of claim 1 wherein the gonadotropin-releasing hormone is administered about 132 hours after the last daily administration of the hormone for synchronizing estrus. 21. The method of claim 1 wherein the gilt is inseminated about 24 to about 28 hours after administration of the gonadotropin-releasing hormone. 22. The method of claim 1 wherein the gilt is inseminated about 20 to about 24 hours after administration of the gonadotropin-releasing hormone.

Details for Patent 9,724,380

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2032-11-28